Prihlásiť sa Zaregistrujte sa zadarmo

Last updated: 15 July 2024 at 6:51pm EST

Jesse Goodman Net Worth



Jesse Goodman biography

Dr. Jesse Goodman M.D. serves as Independent Director of the Company since October 2018. Since March 2014, Dr. Goodman has been the director of the Center on Medical Product Access, Safety and Stewardship, and professor of medicine and attending physician in infectious diseases at Georgetown University. Dr. Goodman also is an infectious disease physician at the Washington DC Veterans Affairs and Walter Reed Medical Centers. Dr. Goodman serves on the board of directors of GlaxoSmithKline plc, a multinational pharmaceutical company, which he joined in 2016 and chairs that board’s science committee. Dr. Goodman also has served as a president and member of the board of trustees of the United States Pharmacopeia since 2015. He is also a member of the board of scientific counselors for infectious diseases of the Centers for Disease Control and Prevention (“CDC”). From 2009 until February 2014, Dr. Goodman served as the chief scientist of the U.S. Food and Drug Administration (“FDA”). Dr. Goodman also served as deputy commissioner for science and public health at the FDA from 2009 through 2012. Prior to that, Dr. Goodman was the director of the FDA’s Center for Biologics Evaluation and Research from 2003 to 2009 and a senior advisor to the FDA commissioner from 1998 through 2000. Prior to his government service, Dr. Goodman was professor of medicine and chief of infectious diseases at the University of Minnesota. Dr. Goodman has served on numerous advisory boards and committees for national and international health care organizations, including the CDC, the National Institute of Health, the World Health Organization and the Coalition on Epidemic Preparedness Innovations. Dr. Goodman received a B.S. in biology from Harvard College, a master’s in public health from the University of Minnesota and an M.D. from the Albert Einstein College of Medicine, and did his residency and fellowship training in medicine, infectious diseases and oncology at the Hospital of the University of Pennsylvania.

What is the salary of Jesse Goodman?

As the Independent Director of Intellia Therapeutics Inc, the total compensation of Jesse Goodman at Intellia Therapeutics Inc is $217,790. There are 14 executives at Intellia Therapeutics Inc getting paid more, with Laura Sepp-Lorenzino having the highest compensation of $1,762,490.



How old is Jesse Goodman?

Jesse Goodman is 68, he's been the Independent Director of Intellia Therapeutics Inc since 2018. There are no older and 19 younger executives at Intellia Therapeutics Inc.

What's Jesse Goodman's mailing address?

Jesse's mailing address filed with the SEC is C/O BIOMX INC., 22 EINSTEIN ST., FLOOR 4, , NESS ZIONA,, L3, 7414003.

Insiders trading at Intellia Therapeutics Inc

Over the last 8 years, insiders at Intellia Therapeutics Inc have traded over $210,567,884 worth of Intellia Therapeutics Inc stock and bought 1,285,277 units worth $23,117,886 . The most active insiders traders include Carl L Gordon, Jean Francois Formela a Bros. Advisors Lpbaker Feli.... On average, Intellia Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $1,357,638. The most recent stock trade was executed by Eliana Clark on 1 July 2024, trading 405 units of NTLA stock currently worth $9,287.



What does Intellia Therapeutics Inc do?

intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the



What does Intellia Therapeutics Inc's logo look like?

Intellia Therapeutics Inc logo

Intellia Therapeutics Inc executives and stock owners

Intellia Therapeutics Inc executives and other stock owners filed with the SEC include: